Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952611 | 0.86 | NLRP3 (0.46) | NLRP3LMNATP53SMN1; SMN2MAPT | |
| SCHEMBL25815549 | 0.84 | NLRP3 (0.44) | NLRP3LMNAALOX15 | |
| SCHEMBL23952591 | 0.81 | NLRP3 (0.55) | NLRP3LMNAALOX15 | |
| SCHEMBL23952018 | 0.80 | NLRP3 (0.42) | NLRP3LMNAALOX15 | |
| SCHEMBL23952041 | 0.80 | NLRP3 (0.63) | NLRP3LMNAALOX15 | |
| SCHEMBL23952044 | 0.80 | NLRP3 (0.47) | NLRP3LMNA | |
| SCHEMBL25816652 | 0.80 | NLRP3 (0.47) | NLRP3LMNAALOX15 | |
| SCHEMBL23952368 | 0.80 | NLRP3 (0.47) | NLRP3LMNAMAPTALOX15 | |
| SCHEMBL23952040 | 0.80 | NLRP3 (0.47) | NLRP3LMNATP53MAPTALOX15 | |
| SCHEMBL23952037 | 0.79 | NLRP3 (0.45) | NLRP3LMNATP53SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135842-B1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| EP-4135842-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN Pharmaceutica NV (BE) | 2023-02-22 | — | — | EP | disclosed |
| CN-115485026-A | Pyrazolo [1,2-D ] [1,2,4] triazin-2-yl-acetamides as NLRP3 inflammatory pathway inhibitors | 詹森药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021209539-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885LMNA 2529/4885TP53 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.